The endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) is elevated in both animal models of chronic inflammatory disorders as well as in patients with chronic inflammatory disease. In vivo data suggest that ADMA can increase the number of circulating monocytes and possibly affect their adhesion potential in vitro. The aim of our study was to evaluate possible effects of chronically elevated levels of ADMA on white blood cell count (WBC), leukocyte subsets, and WBC distribution pattern using a model of chronic exogenous ADMA infusion. Male Sprague–Dawley rats (n = 20, 10 weeks of age) were randomized to receive either (1) isotonic saline or (2) ADMA applied by osmotic mini pumps. After 28 days of infusion, all animals were sacrificed for blood and tissue sampling. WBC count, flow cytometry for subtype assessment, and histological assessment were performed. Over a time period of 28 days, continuous ADMA infusion significantly increased mean plasma levels (1.26 ± 0.07 μmol/l) as compared to saline infusion (0.57 ± 0.02 μmol/l). Clinical side effects were not observed. Despite a physiologically relevant rise in ADMA plasma levels, measured by decrease of the l-arginine/AMDA ratio—a surrogate parameter of NO production capacity—there was no effect on WBC count or pattern of leukocyte subsets. Numbers and morphology of peripheral blood cells as well as number of NK-cells leveling liver and spleen were not affected by chronic ADMA infusion. Chronically elevated ADMA levels in otherwise healthy rats did not affect WBC counts or leukocyte subsets. Furthermore, anemia frequently found in patients with progressive renal failure and elevated ADMA levels, was not observed. In a chronic inflammatory state, elevated ADMA levels themselves are rather the result than the cause of the underlying inflammatory process.
This is a preview of subscription content, log in to check access.
This study is supported by a grant of the Werner Jackstädt Stiftung to JTK and HK.
Conflict of interest
The authors declare that they have no conflict of interest.
Zoccali C, Benedetto FA, Maas R, Mallamaci F, Tripepi G, Malatino LS, Boger R (2002) Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 13:490–496PubMedCrossRefGoogle Scholar
Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141–1146PubMedCrossRefGoogle Scholar
Schroecksnadel K, Weiss G, Stanger O, Teerlink T, Fuchs D (2007) Increased asymmetric dimethylarginine concentrations in stimulated peripheral blood mononuclear cells. Scand J Immunol 65:525–529PubMedCrossRefGoogle Scholar
Chen M, Li Y, Yang T, Wang Y, Bai Y, Xie X (2008) ADMA induces monocyte adhesion via activation of chemokine receptors in cultured THP-1 cells. Cytokine 43:149–159PubMedCrossRefGoogle Scholar
Greenberg SS, Ouyang J, Zhao X, Giles TD (1998) Human and rat neutrophils constitutively express neural nitric oxide synthase mRNA. Nitric Oxide 2:203–212PubMedCrossRefGoogle Scholar
Roman A, Legallo R, McGahren ED (2004) Blocking of endogenous nitric oxide increases white blood cell accumulation in rat lung. J Pediatr Surg 39:48–52PubMedCrossRefGoogle Scholar
Michurina T, Krasnov P, Balazs A, Nakaya N, Vasilieva T, Kuzin B, Khrushchov N, Mulligan RC, Enikolopov G (2004) Nitric oxide is a regulator of hematopoietic stem cell activity. Mol Ther 10:241–248PubMedCrossRefGoogle Scholar
Kurz K, Teerlink T, Sarcletti M, Weiss G, Zangerle R, Fuchs D (2009) Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res 60:508–514PubMedCrossRefGoogle Scholar
Molnar M, Suto T, Toth T, Hertelendy F (1994) Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol 170:1458–1466PubMedGoogle Scholar
Kielstein JT, Boger RH, Bode-Boger SM, Schaffer J, Barbey M, Koch KM, Frolich JC (1999) Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 10:594–600PubMedGoogle Scholar
Chen LY, Mehta JL (1996) Variable effects of l-arginine analogs on l-arginine-nitric oxide pathway in human neutrophils and platelets may relate to different nitric oxide synthase isoforms. J Pharmacol Exp Ther 276:253–257PubMedGoogle Scholar
Bedoui S, Kuhlmann S, Nave H, Drube J, Pabst R, von Horsten S (2001) Differential effects of neuropeptide Y (NPY) on leukocyte subsets in the blood: mobilization of B-1-like B-lymphocytes and activated monocytes. J Neuroimmunol 117:125–132PubMedCrossRefGoogle Scholar